{"id":"https://openalex.org/W2015294539","doi":"https://doi.org/10.3816/cbc.2007.n.049","title":"Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes","display_name":"Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes","publication_year":2007,"publication_date":"2007-12-01","ids":{"openalex":"https://openalex.org/W2015294539","doi":"https://doi.org/10.3816/cbc.2007.n.049","mag":"2015294539","pmid":"https://pubmed.ncbi.nlm.nih.gov/18269774"},"language":"en","primary_location":{"id":"doi:10.3816/cbc.2007.n.049","doi":"https://doi.org/10.3816/cbc.2007.n.049","is_oa":false,"landing_page_url":"https://doi.org/10.3816/cbc.2007.n.049","pdf_url":null,"source":{"id":"https://openalex.org/S57202346","display_name":"Clinical Breast Cancer","issn_l":"1526-8209","issn":["1526-8209","1938-0666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Breast Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042123072","display_name":"Joanne Lorraine Blum","orcid":"https://orcid.org/0000-0002-7951-6645","observed_orcids":["https://orcid.org/0000-0002-7951-6645"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Joanne L. Blum","raw_affiliation_strings":["Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA. joanne.blum@usoncology.com","Baylor Charles A. Sammons Cancer Center, Dallas, Texas","Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Charles A. Sammons Cancer Center, Dallas, Texas, USA. joanne.blum@usoncology.com","institution_ids":[]},{"raw_affiliation_string":"Baylor Charles A. Sammons Cancer Center, Dallas, Texas","institution_ids":[]},{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059365988","display_name":"Michael A. Savin","orcid":"https://orcid.org/0000-0002-4301-5849","observed_orcids":["https://orcid.org/0000-0002-4301-5849"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Savin","raw_affiliation_strings":["Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111917213","display_name":"Gerald M. Edelman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gerald Edelman","raw_affiliation_strings":["Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010188774","display_name":"John Pippen","orcid":"https://orcid.org/0000-0003-3522-9780","observed_orcids":["https://orcid.org/0000-0003-3522-9780"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John E. Pippen","raw_affiliation_strings":["Baylor Charles A. Sammons Cancer Center, Dallas, Texas","Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Charles A. Sammons Cancer Center, Dallas, Texas","institution_ids":[]},{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075481530","display_name":"Nicholas J. Robert","orcid":"https://orcid.org/0000-0002-8491-5392","observed_orcids":["https://orcid.org/0000-0002-8491-5392"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicholas J. Robert","raw_affiliation_strings":["US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028702563","display_name":"Brian V. Geister","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian V. Geister","raw_affiliation_strings":["US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003827285","display_name":"Robert L. Kirby","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert L. Kirby","raw_affiliation_strings":["Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040949476","display_name":"Alicia Clawson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166201","display_name":"Abraxis (United States)","ror":"https://ror.org/05r1gew95","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166201"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alicia Clawson","raw_affiliation_strings":["Abraxis BioScience, Inc, Los Angeles, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Abraxis BioScience, Inc, Los Angeles, CA","institution_ids":["https://openalex.org/I4210166201"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5071432873","display_name":"Joyce O\u2019Shaughnessy","orcid":"https://orcid.org/0000-0002-2955-5523","observed_orcids":["https://orcid.org/0000-0002-2955-5523","https://orcid.org/0000-0001-6764-2807"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]},{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joyce A. O'Shaughnessy","raw_affiliation_strings":["Baylor Charles A. Sammons Cancer Center, Dallas, Texas","Texas Oncology, P.A., Dallas","US Oncology, Houston, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Charles A. Sammons Cancer Center, Dallas, Texas","institution_ids":[]},{"raw_affiliation_string":"Texas Oncology, P.A., Dallas","institution_ids":["https://openalex.org/I2800124591"]},{"raw_affiliation_string":"US Oncology, Houston, Texas","institution_ids":["https://openalex.org/I4210151469"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5042123072"],"corresponding_institution_ids":["https://openalex.org/I2800124591","https://openalex.org/I4210151469"],"apc_list":{"value":3470,"currency":"USD","value_usd":3470},"apc_paid":null,"fwci":6.6136,"has_fulltext":false,"cited_by_count":172,"citation_normalized_percentile":{"value":0.97468113,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":100},"biblio":{"volume":"7","issue":"11","first_page":"850","last_page":"856"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9800000190734863},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9729999899864197},{"id":"https://openalex.org/keywords/taxane-refractory-disease","display_name":"taxane-refractory disease","score":0.8899999856948853},{"id":"https://openalex.org/keywords/once-weekly-dosing","display_name":"weekly dosing","score":0.7799999713897705},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5450000166893005},{"id":"https://openalex.org/keywords/response-rate","display_name":"response rate","score":0.6600000262260437},{"id":"https://openalex.org/keywords/stable-disease","display_name":"stable disease","score":0.7850000262260437},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9700000286102295},{"id":"https://openalex.org/keywords/peripheral-neuropathy","display_name":"peripheral neuropathy","score":0.8519999980926514},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.9649999737739563},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8762840032577515},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.8732554912567139},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7887287735939026},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.7214013934135437},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6726897954940796},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6369112730026245},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.5665082931518555},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5612737536430359},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5282708406448364},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4657866060733795},{"id":"https://openalex.org/C2776125364","wikidata":"https://www.wikidata.org/wiki/Q169219","display_name":"Albumin","level":2,"score":0.44402721524238586},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.4200177788734436},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3642546832561493},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.34590256214141846},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.12807685136795044}],"mesh":[{"descriptor_ui":"D000008","descriptor_name":"Abdominal Neoplasms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000068196","descriptor_name":"Albumin-Bound Paclitaxel","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000418","descriptor_name":"Albumins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D001859","descriptor_name":"Bone Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008113","descriptor_name":"Liver Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000556","qualifier_name":"secondary","is_major_topic":false},{"descriptor_ui":"D008207","descriptor_name":"Lymphatic Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020360","descriptor_name":"Neoadjuvant Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D043823","descriptor_name":"Taxoids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3816/cbc.2007.n.049","doi":"https://doi.org/10.3816/cbc.2007.n.049","is_oa":false,"landing_page_url":"https://doi.org/10.3816/cbc.2007.n.049","pdf_url":null,"source":{"id":"https://openalex.org/S57202346","display_name":"Clinical Breast Cancer","issn_l":"1526-8209","issn":["1526-8209","1938-0666"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Breast Cancer","raw_type":"journal-article"},{"id":"pmid:18269774","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18269774","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical breast cancer","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1885306047","https://openalex.org/W1939003096","https://openalex.org/W1946759281","https://openalex.org/W2078775260","https://openalex.org/W2139248078","https://openalex.org/W2144536924","https://openalex.org/W2153017356","https://openalex.org/W2155808778","https://openalex.org/W2164934025","https://openalex.org/W2231186601"],"related_works":["https://openalex.org/W2006416360","https://openalex.org/W2376718567","https://openalex.org/W4391216330","https://openalex.org/W2796977334","https://openalex.org/W2760627575","https://openalex.org/W2178665864","https://openalex.org/W2468915489","https://openalex.org/W2022678011","https://openalex.org/W2115401462","https://openalex.org/W29090612"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":10},{"year":2016,"cited_by_count":11},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":12},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":18}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}